Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: J Pharmacol Toxicol Methods. 2012 Aug 25;66(3):246–256. doi: 10.1016/j.vascn.2012.08.167

Fig. 4. Opposite effects of an L-type Ca2+ inhibitor and activator on calcium transients in hiPSC-CMs.

Fig. 4

(a,b) Average calcium transient curves (left) and dose-response plot (right) for the FWHM in hiPSC-CMs treated with the L-type Ca2+ channel blocker verapamil (a) or channel activator Bay K 8644 (b). Calcium transients were averaged between well replicates and aligned at the beginning of the upstroke.